Incidence of venous thromboembolism in patients with solid cancers in Japan: retrospective study of 2735 patients.
Cancer-associated venous thromboembolism
Incidence
Solid malignancy
Venous thromboembolism
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
30
03
2021
accepted:
25
05
2021
revised:
23
05
2021
pubmed:
7
6
2021
medline:
1
9
2021
entrez:
6
6
2021
Statut:
ppublish
Résumé
The incidence of cancer-associated venous thromboembolism (CA-VTE) in Japan has not been fully investigated. Clinicopathological information from patients with solid malignancies who first visited our department between November 2011 and March 2018 were retrospectively reviewed from medical records. The primary outcome was incidence of CA-VTE, defined as deep-vein thrombosis (DVT) and/or pulmonary embolism (PE). On median follow-up of 187 days, 91 of 2735 patients (3.3%) developed CA-VTE during their clinical course, giving an incidence rate of 40.7 per 1000 person-years. Of the 91 patients, 75 (82%) were diagnosed with DVT alone, 6 (7%) with PE alone, and 10 (11%) with both DVT and PE. CA-VTE was most frequent in non-small cell lung cancer (10.8%), followed by cancer of unknown origin (5.8%). Forty-four patients (48%) had one or more symptoms at the initial diagnosis of VTE. Five patients (6%) had a normal D-dimer level (≤ 1.0 µg/mL); of these, 2 were asymptomatic. In this retrospective study, the incidence of CA-VTE in Japanese patients with cancer was equivalent to that in Western populations. Approximately half of CA-VTE patients were asymptomatic and 6% had normal D-dimer levels, indicating the need for closer attention to occult CA-VTE.
Sections du résumé
BACKGROUND
BACKGROUND
The incidence of cancer-associated venous thromboembolism (CA-VTE) in Japan has not been fully investigated.
METHODS AND RESULTS
RESULTS
Clinicopathological information from patients with solid malignancies who first visited our department between November 2011 and March 2018 were retrospectively reviewed from medical records. The primary outcome was incidence of CA-VTE, defined as deep-vein thrombosis (DVT) and/or pulmonary embolism (PE). On median follow-up of 187 days, 91 of 2735 patients (3.3%) developed CA-VTE during their clinical course, giving an incidence rate of 40.7 per 1000 person-years. Of the 91 patients, 75 (82%) were diagnosed with DVT alone, 6 (7%) with PE alone, and 10 (11%) with both DVT and PE. CA-VTE was most frequent in non-small cell lung cancer (10.8%), followed by cancer of unknown origin (5.8%). Forty-four patients (48%) had one or more symptoms at the initial diagnosis of VTE. Five patients (6%) had a normal D-dimer level (≤ 1.0 µg/mL); of these, 2 were asymptomatic.
CONCLUSIONS
CONCLUSIONS
In this retrospective study, the incidence of CA-VTE in Japanese patients with cancer was equivalent to that in Western populations. Approximately half of CA-VTE patients were asymptomatic and 6% had normal D-dimer levels, indicating the need for closer attention to occult CA-VTE.
Identifiants
pubmed: 34091877
doi: 10.1007/s12185-021-03167-x
pii: 10.1007/s12185-021-03167-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
319-324Informations de copyright
© 2021. Japanese Society of Hematology.
Références
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632–4. https://doi.org/10.1111/j.1538-7836.2007.02374.x .
doi: 10.1111/j.1538-7836.2007.02374.x
pubmed: 17319909
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–7. https://doi.org/10.1182/blood-2007-10-116327 .
doi: 10.1182/blood-2007-10-116327
pubmed: 18216292
pmcid: 18216292
Mandalà M, Barni S, Prins M, Labianca R, Tondini C, Russo L, et al. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol Off J Eur Soc Med Oncol. 2010;21:871–6. https://doi.org/10.1093/annonc/mdp354 .
doi: 10.1093/annonc/mdp354
Gary T, Belaj K, Steidl K, Pichler M, Eisner F, Stöger H, et al. Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: impact on short-term survival. Br J Cancer. 2012;107:1244–8. https://doi.org/10.1038/bjc.2012.401 .
doi: 10.1038/bjc.2012.401
pubmed: 22968652
pmcid: 3494438
Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380:720–8. https://doi.org/10.1056/NEJMoa1814630 .
doi: 10.1056/NEJMoa1814630
pubmed: 30786186
Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost. 2011;106:371–8. https://doi.org/10.1160/TH10-12-0789 .
doi: 10.1160/TH10-12-0789
pubmed: 21713322
Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38:496–520. https://doi.org/10.1200/JCO.19.01461 .
doi: 10.1200/JCO.19.01461
pubmed: 31381464
Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT study. Arch Intern Med. 1991;151:933–8. https://doi.org/10.1001/archinte.1991.00400050081016 .
doi: 10.1001/archinte.1991.00400050081016
pubmed: 2025141
Sakuma M, Nakamura M, Yamada N, Ota S, Shirato K, Nakano T, et al. Venous thromboembolism: deep vein thrombosis with pulmonary embolism, deep vein thrombosis alone, and pulmonary embolism alone. Circ J. 2009;73:305–9. https://doi.org/10.1253/circj.cj-08-0372 .
doi: 10.1253/circj.cj-08-0372
pubmed: 19096193
Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458–64. https://doi.org/10.1001/archinte.166.4.458 .
doi: 10.1001/archinte.166.4.458
pubmed: 16505267
Kitayama H, Kondo T, Sugiyama J, Kurimoto K, Nishino Y, Hirayama M, et al. Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study. BMC Cancer. 2017;17:351. https://doi.org/10.1186/s12885-017-3326-1 .
doi: 10.1186/s12885-017-3326-1
pubmed: 28525975
pmcid: 5438527
Zwicker JI, Connolly G, Carrier M, Kamphuisen PW, Lee AYY. Catheter-associated deep vein thrombosis of the upper extremity in cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2014;12:796–800. https://doi.org/10.1111/jth.12527 .
doi: 10.1111/jth.12527
pubmed: 24548519
Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9:1–19. https://doi.org/10.1371/journal.pmed.1001275 .
doi: 10.1371/journal.pmed.1001275
Yu Y-B, Gau J-P, Liu C-Y, Yang M-H, Chiang S-C, Hsu H-C, et al. A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system. Thromb Haemost. 2012;108:225–35. https://doi.org/10.1160/TH12-01-0010 .
doi: 10.1160/TH12-01-0010
pubmed: 22534880
Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet (London, England). 1995;346:1133–4. https://doi.org/10.1016/s0140-6736(95)91803-5 .
doi: 10.1016/s0140-6736(95)91803-5
Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev. 2002;3(3):141-6. https://doi.org/10.1046/j.1467-789x.2002.00065.x .
Klovaite J, Benn M, Nordestgaard BG. Obesity as a causal risk factor for deep venous thrombosis: a Mendelian randomization study. J Intern Med. 2015;277:573–84. https://doi.org/10.1111/joim.12299 .
doi: 10.1111/joim.12299
pubmed: 25161014
Nomura T, Suehisa E, Kawasaki T, Okada A. Frequency of protein S deficiency in general Japanese population. Thromb Res. 2000;100:367–71. https://doi.org/10.1016/s0049-3848(00)00337-6 .
doi: 10.1016/s0049-3848(00)00337-6
pubmed: 11150577
Kinoshita S, Iida H, Inoue S, Watanabe K, Kurihara M, Wada Y, et al. Protein S and protein C gene mutations in Japanese deep vein thrombosis patients. Clin Biochem. 2005;38:908–15. https://doi.org/10.1016/j.clinbiochem.2005.05.006 .
doi: 10.1016/j.clinbiochem.2005.05.006
pubmed: 15978566
Tanizawa Y, Bando E, Kawamura T, Tokunaga M, Makuuchi R, Iida K, et al. Prevalence of deep venous thrombosis detected by ultrasonography before surgery in patients with gastric cancer: a retrospective study of 1140 consecutive patients. Gastric Cancer. 2017;20:878–86. https://doi.org/10.1007/s10120-016-0677-2 .
doi: 10.1007/s10120-016-0677-2
pubmed: 27987041
Ebina Y, Uchiyama M, Imafuku H, Suzuki K, Miyahara Y, Yamada H. Risk factors for deep venous thrombosis in women with ovarian cancer. Medicine (Baltimore). 2018;97:e11009. https://doi.org/10.1097/MD.0000000000011009 .
doi: 10.1097/MD.0000000000011009
Haen P, Mege D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Thrombosis risk associated with head and neck cancer: a review. Int J Mol Sci. 2019;20:2838. https://doi.org/10.3390/ijms20112838 .
doi: 10.3390/ijms20112838
pmcid: 6600456
Decousus H, Bourmaud A, Fournel P, Bertoletti L, Labruyère C, Presles E, et al. Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP). Blood. 2018;132:707–16. https://doi.org/10.1182/blood-2018-03-837153 .
doi: 10.1182/blood-2018-03-837153
pubmed: 29980524
Wells PS, Owen C, Doucette S, Fergusson D, Tran H. Does this patient have deep vein thrombosis? JAMA. 2006;295:199–207. https://doi.org/10.1001/jama.295.2.199 .
doi: 10.1001/jama.295.2.199
pubmed: 16403932
Geersing GJ, Zuithoff NPA, Kearon C, Anderson DR, Ten Cate-Hoek AJ, Elf JL, et al. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ. 2014;348:g1340. https://doi.org/10.1136/bmj.g1340 .
doi: 10.1136/bmj.g1340
pubmed: 24615063
pmcid: 3948465